DIOVAN HCT

LOE Approaching

valsartan and hydrochlorothiazide

Novartis

NDAORALTABLET

Approved

Mar 1998

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Indications (10)

hypertension to lower blood pressure to lower blood pressure: In patients not adequately controlled with monotherapy ()nonfatal cardiovascular events primarily strokes myocardial infarctions heart failure Diovan HCT 320/25 mg based upon baseline systolic diastolic blood pressure

Clinical Trials (2)

NCT00386607Phase 3Completed

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Started Oct 2006

601 enrolled

Hypertension

NCT00171080Phase 3Completed

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Started Apr 2004

86 enrolled

Hypertension

Company

External Resources

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers